Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

In This Article:

Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc.

Joint meeting to be held in Las Vegas, May 14-17

Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute

Topline study results demonstrate clinically meaningful improvements in OLP

Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity

PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that its abstract on LP-10 for the treatment of Oral Lichen Planus (OLP) has been accepted for podium presentation at the 2025 joint international meeting of the American Academy of Oral Medicine (AAOM) and European Association of Oral Medicine (EAOM). The meeting will take place May 14–17 in Las Vegas. The presentation will be delivered by Dr. Alessandro Villa, Chief of Oral Medicine, Oral Oncology and Dentistry, and Professor at Herbert Wertheim College of Medicine, Miami Cancer Institute, on May 15.

The abstract, titled "Liposomal Tacrolimus (LP-10) Oral Rinse for the Treatment of Oral Lichen Planus: Topline Analysis of a Phase 2a Multicenter Dose-Ranging Trial," presents data from an ongoing trial evaluating LP-10, a liposomal formulation of tacrolimus, in patients with symptomatic OLP—a chronic inflammatory condition of the oral mucosa that can cause pain, white patches, swelling, and ulcerations. The oral rinse has demonstrated good tolerability and produced clinically meaningful improvements.

“As the global oral medicine community gathers this spring, we’re proud to present promising new data toward the goal of providing a safe and effective treatment for Oral Lichen Planus,” said Jonathan Kaufman, CEO and co-founder of Lipella. “Our topline results show significant improvement after just four weeks of treatment. This is a meaningful step forward for a patient population in need of recognition, support, and therapeutic options. We look forward to sharing final topline results from the fully enrolled trial, which are expected in the second quarter of 2025.”

“We observed statistically significant improvements across clinical measures, along with visible reductions in inflammation and resolution of ulcerative lesions in some patients,” said Dr. Michael Chancellor, Chief Medical Officer and Co-Founder of Lipella. “These effects were most evident at the end of the treatment period, supporting the clinical relevance of LP-10’s localized activity. Taken together, the data highlight LP-10’s potential as a non-steroidal therapeutic option for a chronic condition with no FDA-approved treatments.”